Recent prostate cancer screening trials have given conflicting results and it is unclear how to
reduce prostate cancer mortality while minimising overdiagnosis and overtreatment …

Guidelines for prostate specific antigen (PSA) testing in Australia recommend that men at
average risk of prostate cancer who have been informed of the benefits and harms, and who …

Abstract Background Studies conducted in Swedish populations have shown that men with
lowest prostate-specific antigen (PSA) levels at ages 44–50 years and 60 years have very …

Importance The diagnostic activity for prostate cancer has increased during the past
decades. However, the benefit and harm of the increased diagnostic activity have not been …

Background. Simulation models are essential tools for estimating benefits of cancer
screening programs. Such models include a screening-effect model that represents how …

Background Although prostate-specific antigen (PSA) testing is common, little is known
about the pattern of retesting by either PSA values or subsequent prostate biopsies. Poor …

Background In a previous publication from the Göteborg randomised screening trial from
2010, biennial prostate-specific antigen (PSA) screening for men≤ 69 yr of age was shown …

Background: Making an informed decision about treating a prostate cancer detected after a
routine prostate-specific antigen (PSA) test requires knowledge about disease natural …

Abstract A 21% prostate cancer (PCa) mortality reduction was observed in the European
Randomized Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. A …

Background There is ongoing debate about the harms and benefits of a national prostate
cancer screening programme. Several model-based cost-effectiveness analyses have been …